Minapharm Pharmaceuticals SAE
Minapharm Pharmaceuticals SAE has a debt-to-equity ratio of 1.27, indicating a moderate level of leverage, and a current ratio of 1.25, suggesting it has sufficient short-term assets to cover its short-term liabilities. The company's liquidity position is assessed as medium, with a negative net cash position after subtracting total debt. In terms of profitability, Minapharm's return on equity is 3.65%, and its return on assets is 1.31%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The company's operating income margin is 12.24%, and its net income margin is 2.77%, which are key metrics for evaluating its efficiency and profitability. Minapharm's revenue is primarily concentrated in Egypt, with a significant portion of its sales derived from domestic operations. The company's international distribution efforts are limited, and it does not disclose specific geographic revenue breakdowns in its latest financial report. The company's production is divided into seven lines, including Gastroenterology, Ophthalmology, and Cardiology, but it does not provide detailed segment revenue figures. The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. Minapharm's capital expenditure for the period was -919,053,650 EGP, indicating a reduction in investment in physical assets. The company's free cash flow is negative at -513,399,410 EGP, which may limit its ability to fund future growth initiatives. The risk assessment for Minapharm indicates a medium liquidity risk and a low dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could affect its financial flexibility. The company's dilution potential is low, as there is no significant difference between basic and diluted shares outstanding. Recent events and filings for Minapharm do not indicate any major operational or financial changes. The company continues to operate in cooperation with several international pharmaceutical companies and distributes its products within and outside Egypt. No recent transcripts or filings suggest significant strategic shifts or new product launches.
Business. Minapharm Pharmaceuticals SAE is an Egypt-based company engaged in the production and distribution of pharmaceutical products, including betolvex, broncho-vaxom adult, broncho-vaxom infantile, burinex, and other products.
Classification. Minapharm is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry with a confidence level of 0.92.
- Minapharm has a moderate level of leverage with a debt-to-equity ratio of 1.27.
- The company's profitability metrics, including return on equity and return on assets, are below typical industry benchmarks.
- Revenue is primarily concentrated in Egypt, with limited international distribution.
- The company's free cash flow is negative, which may constrain its ability to fund future growth.
- The risk assessment indicates a medium liquidity risk and a low dilution risk.
- # RATIONALES
- **margin_outlook_rationale**: The company's operating and net income margins are below typical industry benchmarks, indicating potential challenges in maintaining profitability.
- **rd_outlook_rationale**: No specific information is provided regarding the company's research and development activities or their impact on future growth.
- Net cash is negative after subtracting total debt.